Effects of atorvastatin on ventricular late potentials and repolarization dispersion in patients with hypercholesterolemia

Kaohsiung Journal of Medical Sciences

Volumn 23, Issue 5, 2007, Pages 217-224

  Chu, Chih Sheng ^a,b   Lee, Kun Tai ^a,b   Lee, Shuo Tsan ^a   Lu, Ye Hsu ^a   Lin, Tsung Hsien ^a,b   Voon, Wen Choi ^a,b   Sheu, Sheng Hsiung ^a,b   Lai, Wen Ter ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atorvastatin; Electrocardiography; Late potentials; QT dispersion; Transmural dispersion

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART REPOLARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; QT DISPERSION; TREATMENT OUTCOME;

EID: 34250753941     PISSN: 1607551X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1607-551X(09)70401-2     Document Type: Article

References (24)

1. Pignone M, Philips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomized trials. BMJ 2000;321:983-6.
2. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
4. De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000;36:766-72.
5. Liu YB, Wu CC, Lu LS, et al. Sympathetic nerve sprouting, electrical remodeling, and increased vulnerability to ventricular fibrillation in hypercholesterolemic rabbits. Circ Res 2003;92:1145-52.
6. Szabo Z, Harangi M, Lorincz I, et al. Effects of hyperlipidemia on QT dispersion in patients with ischemic heart disease. Can J Cardiol 2005;21:847-50.
7. Kayikcioglu M, Can L, Evrengul H, et al. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 2003;90:63-72.
8. Chiu JH, Abdelhadi RH, Chung MK, et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 2005;95:490-1.
9. Vyas AK, Guo H, Moss AJ, et al. MADIT-II research group reduction in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator implantation trial (MADIT)-II. J Am Coll Cardiol 2006;47:769-73.
10. Gualdiero P, Esposito K, Ciotola M, et al. Simvastatin normalized QTc dispersion and reduced ventricular electrical instability in isolated hypercholesterolemia. J Endocrinol Invest 2002;25:RC16-8.
11. Mark L, Katona A. Effect of fluvastatin on QT dispersion: a new pleiotropic effect? Am J Cardiol 2000;85:919-20.
12. Savard P, Rouleau JL, Ferguson J, et al. Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location. Circulation 1997;96: 202-13.
13. Lee KW, Kligfield P, Dower GE, et al. QT dispersion, T-wave projection, and heterogeneity of repolarization in patients with coronary artery disease. Am J Cardiol 2001;87:148-51.
14. Savelieva I, Yap YG, Yi G, et al. Comparative reproducibility of QT, QT peak, and T peak-T end intervals and dispersion in normal subjects, patients with myocardial infarction, and patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 1998;21:2376-81.
15. Lubinski A, Kornacewicz-Jach Z, Wnuk-Wojnar AM, et al. The terminal portion of the T wave: a new electrocardiographic marker of risk of ventricular arrhythmia. Pacing Clin Electrophysiol 2000;23:1957-9.
16. Macfarlane PW, Norrie J. WOSCOPS Executive Committee: looking for prognostic information in the ST-T segment - is it really worth it? J Electrocardiol 2004; (Suppl 37):209-13.
17. Gomes JA, Winters SL, Stewart D, et al. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction based on signal-average electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987;10:349-57.
18. Breithardt G, Cain ME, el-Sherif N, et al. Standards for analysis of ventricular late potentials using high resolution electrocardiography: a statement of a Task Force Committee between European Society of Cardiology, the American Heart Association and the American College of Cardiology. Circulation 1991;83:1481-8.
19. Perkiomaki JS, Koistinen MJ, Yli-Mayry SM, et al. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995; 26:174-9.
20. Bazett H. An analysis of time-relations of electrocardiograms. Heart 1920;7:353-70.
21. Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (London) 2003;105:671-6.
22. Lee KT, Lai WT, Chu CS, et al. Circadian variation of QT dispersion determined by twelve-lead Holter electrocardiography. Cardiology 2003;100:101-2.
23. Molnar J, Zhang F, Weiss J, et al. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.
24. Muller JE, Ludmer PL, Willich SN, et al. Circadian variation in the frequency of sudden cardiac death. Circulation 1987;75:131-8.